Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions

Thomas A. Ciulla; Steven Yeh; Seenu M. Hariprasad

doi:10.3928/23258160-20220617-01

Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions

Thomas A. Ciulla, Steven Yeh, Seenu M. Hariprasad

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	361-366
Number of pages	6
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	53
Issue number	7
DOIs	https://doi.org/10.3928/23258160-20220617-01
State	Published - Jul 2022

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.3928/23258160-20220617-01

Cite this

@article{3eddfc72be7b42f78b796305395ba56b,

title = "Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions",

author = "Ciulla, {Thomas A.} and Steven Yeh and Hariprasad, {Seenu M.}",

note = "Funding Information: Dr. Ciulla has an employment relationship with, and holds equity in, Clearside Biomedical, Inc. Dr. Yeh has received consulting fees from Clearside Biomedical, Bausch and Lomb, and Regenxbio. Dr. Hariprasad is a consultant or on the Speaker{\textquoteright}s Bureau with EyePoint Pharmaceuticals, Allergan, Alimera Sciences, Novartis, Biogen, Bausch & Lomb, and Regeneron.",

year = "2022",

month = jul,

doi = "10.3928/23258160-20220617-01",

language = "English (US)",

volume = "53",

pages = "361--366",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "7",

}

TY - JOUR

T1 - Suprachoroidal Drug Delivery for Clinicians

T2 - Anatomic Principles, Clinical Data in Uveitis, and Future Directions

AU - Ciulla, Thomas A.

AU - Yeh, Steven

AU - Hariprasad, Seenu M.

N1 - Funding Information: Dr. Ciulla has an employment relationship with, and holds equity in, Clearside Biomedical, Inc. Dr. Yeh has received consulting fees from Clearside Biomedical, Bausch and Lomb, and Regenxbio. Dr. Hariprasad is a consultant or on the Speaker’s Bureau with EyePoint Pharmaceuticals, Allergan, Alimera Sciences, Novartis, Biogen, Bausch & Lomb, and Regeneron.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85134745978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134745978&partnerID=8YFLogxK

U2 - 10.3928/23258160-20220617-01

DO - 10.3928/23258160-20220617-01

M3 - Article

C2 - 35858236

AN - SCOPUS:85134745978

SN - 2325-8160

VL - 53

SP - 361

EP - 366

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

IS - 7

ER -

Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this